Skip to content

CogStim, a Pilot Study : Cognitive Rehabilitation Management of HIV-1 Mild Cognitively Impaired Patients Controlled With Antiretroviral Therapy

CogStim, a Pilot Study : Cognitive Rehabilitation Management of HIV-1 Mild Cognitively Impaired Patients Controlled With Antiretroviral Therapy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02343887
Acronym
CogStim
Enrollment
60
Registered
2015-01-22
Start date
2014-11-30
Completion date
2017-10-31
Last updated
2015-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV

Brief summary

Despite undetectable plasma viral load under treatment, about 30% of HIV infected patients show asymptomatic neurocognitive impairment or minor cognitive disorder. These symptoms impact the compliance of the treatment, though its performance and daily life quality. To this day, no therapy tested has proved its efficiency, including the strategy of the antiretroviral therapy (cART) optimization according to the Cerebral Penetration effectiveness Score (CPE). Description of the study: an open prospective comparative monocentric pilote study, randomised in three groups which investigates the efficiency of a 6 months-cognitive rehabilitation program on improving asymptomatic or minor cognitive disorder for undetectable HIV+ patients. This study gathers HIV-1 patients undetectable under stable cART with a good cerebral penetration who develop asymptomatic or minor cognitive disorders connected to HIV infection. Those who have severe psychiatric disorder or who are on medication that could interfere with psychometrical tests will be excluded. Main Objective: to compare the impact of a cognitive rehabilitation program over a 6 months period on the evolution of minor cognitive disorders and asymptomatic patients to a control group and a group treated with psychological support.

Detailed description

This is an open prospective comparative monocentric study, pilote, that randomised 60 patients in three groups of 20. This study will select 18 to 55 years old patients, with HIV infection controlled under antiretroviral therapy stble for 12 months and cognitive impairment objective on two neuropsychological evaluations separated from 6 months at least. All selected patients must have been explored by cerebral RMN or scanner

Interventions

OTHERneuropsychological tests
OTHERSTAI-Y scale for anxiety
OTHERBeck scale for depression

Sponsors

Assistance Publique Hopitaux De Marseille
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

* \- Seropositive for HIV-1 Patient * With a plasma viral load below the limit of detection for minimum 6 months (HIV viral load \<40 copies / ml) * On stable antiretroviral therapy for 12 months, according to the revised optimized subject to the constraints of genotypic resistance and CPE score in the absence of cons-indication to treatment intensive brain penetration (Annex 15) * With cognitive complaint objectified by the cognitive complaint questionnaire (Appendix 9: score 3 or 1 positive response among the items C4, C5, C7, C8) and cognitive impairment found by an alteration of at least two cognitive fields assessed by psychometric tests for at least 6 months * 18 \<age \<55 years * No defined by a marked depression scale score of Beck \<16 (Appendix 13) * No marked anxiety defined by a T score\> 55 on the scale of Spielberger STAI-Y (Annex 14) * Insured under the social security * Who signed the consent form. * Recent brain imaging excluding other causes of cognitive impairment (MRI or CT brain injected injected so-indication against MRI)

Exclusion criteria

* A patient diagnosed and followed for more than six months psychiatric disorder that could interfere with psychometric assessment * Patients with a poor understanding of French, * Patients with active opportunistic infection of the CNS or with neurological sequelae. * History of head trauma * Active Substance excluding cannabis * Patient for which a change of antiretroviral therapy is provided within 12 months * Patient for which interferon treatment is provided within 12 months * Patient placed under guardianship, * Patient with HIV-related dementia * Liver cirrhosis Child B or C (Annex 16) * Severe renal impairment (creatinine clearance by Cockcroft \<30 ml / min)

Design outcomes

Primary

MeasureTime frameDescription
cognitive remediation strategy (BREF test)6 months\- BREF test
cognitive remediation strategy (grooved pegboard test)6 months\- grooved pegboard test
cognitive remediation strategy (RLRI-16 test6.)6 months\- RLRI-16 test6.
cognitive remediation strategy (Digit Symbol Substitution Test)6 months\- Digit Symbol Substitution Test

Secondary

MeasureTime frameDescription
impact on daily life quality (SF-12 Medical Outcomes Study Short-Form General Health Survey)6 monthsSF-12 Medical Outcomes Study Short-Form General Health Survey
impact on daily life quality (Trail Making Test)6 months-Trail Making Test

Countries

France

Contacts

Primary ContactOlivia ZAEGEL- FAUCHER
olivia.zaegel@ap-hm.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026